Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Comprehensive Assessment of BCR-ABL1 Gene Expression and Genetic Variations by qRT-PCR and NGS Assays in Chronic Myeloid Leukemia Patients Who Are Treated With Ponatinib (CAP Study)

NCT06945146 is registered in ClinicalTrials.gov with Dong-Wook Kim as lead sponsor.

NCT NCT06945146
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06945146 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Comprehensive Assessment of BCR-ABL1 Gene Expression and Genetic Variations by qRT-PCR and NGS Assays in Chronic Myeloid Leukemia Patients Who Are Treated With Ponatinib (CAP Study)
Lead sponsor
Dong-Wook Kim
Phase
Observational
Overall status
Completed
Start date
September 1, 2020
Completion date
September 25, 2024
Enrollment
65 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelogenous leukemia, bcr-abl1 positive